Integrated
Diagnostics Inc. is developing diagnostics that measure the levels of
hundreds of proteins in blood simultaneously to detect early stage diseases. The
company initially plans to translate its extensive academic partnerships into
clinical tests for lung cancer and Alzheimer's disease, where current
diagnostic procedures are inadequate, invasive or impractical.
Most blood diagnostics are
antibody-based and detect a limited number of proteins, which in turn limits
their predictive power.